685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL

• Koby Kidder,
• Rita N Barcia,
• Stephen Fogelson,
• Candida Fratazzi,
• Nathanael McCurley

Affiliations

Koby Kidder

Aff266 grid.256304.60000000419367400Georgia State University Atlanta GA USA

Rita N Barcia

1SIRPant Immunotherapeutics, Hummelstown, PA, USA

Stephen Fogelson

2Develotron, LLC, Hillsborough, NH, USA

Candida Fratazzi

3BBCR, Cambridge, MA, USA

Nathanael McCurley

1SIRPant Immunotherapeutics, Hummelstown, PA, USA